Canaccord Genuity Maintains Buy on BridgeBio Pharma, Raises Price Target to $108

Benzinga · 1d ago
Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $106 to $108.